09:41 AM EDT, 09/24/2024 (MT Newswires) -- Immutep ( IMMP ) said Tuesday it received approximately 2.2 million euros ($2.5 million) as research and development tax incentive cash payment from the French Government under the Credit d'Impot Recherche scheme.

The company said it qualified for the incentive through its Immutep S.A.S. subsidiary, which conducted R&D activities in France in 2023. Under the research tax credit scheme, the French government reimburses 30% of eligible R&D expenses of French companies.

The funds will be used for the global clinical development of eftilagimod alpha and IMP761, Immutep ( IMMP ) said.

Price: 2.2200, Change: -0.07, Percent Change: -3.06